Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3175
Title: | Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry | Authors: | Gentles, T. L. Weintraub, R. G. Justo, R. N. Grigg, L. E. Radford, D. J. Hardikar, W. Cheung, M. Cain, T. M. Rao, P. Alexander, S. I. Ayer, J. Verrall, C. Du Plessis, K. Chapman, J. Rice, K. Barry, J. Zannino, D. Iyengar, A. J. Wilson, T. G. d'Udekem, Y. Winlaw, D. S. Cordina, R. L. Celermajer, D. S. Wheaton, G. R. Bullock, A. |
Issue Date: | 2018 | Source: | 273 , 2018, p. 100-107 | Pages: | 100-107 | Journal: | International Journal of Cardiology | Abstract: | Background: Hepatic and renal dysfunction have been observed in survivors of the Fontan procedure, however their incidence and associated factors remain poorly defined. Methods: A total of 152 participants from a Registry of 1528 patients underwent abdominal ultrasound, transient elastography (FibroScan), serum fibrosis score (FibroTest), in vivo Tc-99m DTPA measurement of glomerular filtration rate (mGFR), and urine albumin-creatinine ratio (ACR). Results: Mean age and time since Fontan were 19.8 ± 9.3 and 14.1 ± 7.6 years, respectively. Features suggestive of hepatic fibrosis were observed on ultrasound in 87/143 (61%) and no patient was diagnosed with hepatocellular carcinoma. FibroScan median kPa was ≥10 in 117/133 (88%), ≥15 in 75/133 (56%), and ≥20 in 41/133 (31%). Fifty-four patients (54/118, 46%) had a FibroTest score ≥0.49 (equivalent to ≥F2 fibrosis). FibroTest score correlated with FibroScan value (r = 0.24, p = 0.015) and ACR (r = 0.29, p = 0.002), and patients with ultrasound features of hepatic fibrosis had a higher FibroScan median kPa (19.5 vs 15.4, p = 0.002). Renal impairment was mild (mGFR 60–89 ml/min/1.73 m2) in 46/131 (35%) and moderate (mGFR 30–59 ml/min/1.73 m2) in 3/131 (2%). Microalbuminuria was detected in 52/139 participants (37%). By multivariable analysis, time since Fontan was associated with increased FibroScan median kPa (β = 0.89, 95% CI 0.54–1.25, p = 0.002) and decreased mGFR (β = −0.77, 95% CI −1.29–0.24, p = 0.005). Conclusions: In the second decade after Fontan hepatic and renal structure and function are abnormal in a significant number of patients: close to 60% have ultrasonographic evidence of structural hepatic abnormalities, 46% have elevated serum hepatic fibrosis scores, and 57% have either reduced glomerular filtration rate or microalbuminuria. Hepatic and renal function should be monitored for potential impacts on outcomes after Fontan completion.L20009832192018-07-31 | DOI: | 10.1016/j.ijcard.2018.07.118 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2000983219&from=exporthttp://dx.doi.org/10.1016/j.ijcard.2018.07.118 | | Keywords: | FibroScan;elastographliver function test kit;pentetic acid;technetium 99m;abdominal radiography;adult;article;Australian and New Zealand Fontan Registry;child;controlled study;correlational study;cross-sectional study;echography;female;Fontan procedure;glomerulus filtration rate;human;in vivo study;kidney failure;kidney function;liver cell carcinoma;liver failure;liver fibrosis;liver function;major clinical study;male;microalbuminuria;mild renal impairment;moderate renal impairment;patient monitoring;priority journal;register;school child;transient elastography;treatment outcome;young adult;FibroTest | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.